# Aleksandar Sekulic

Source: https://onco.cc/people/aleksandar-sekulic/  
OnCo record `aleksandar-sekulic` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Mayo Clinic dermatologist who led ERIVANCE, the trial that established vismodegib, the first Hedgehog pathway inhibitor, for advanced basal cell carcinoma.

## Summary

Aleksandar Sekulic is a dermatologist and physician-scientist at Mayo Clinic in Arizona. He was first author of the 2012 New England Journal of Medicine report of ERIVANCE BCC, the phase 2 trial in which the Hedgehog pathway inhibitor vismodegib produced responses in most patients with locally advanced and in a third of those with metastatic basal cell carcinoma, the basis of the drug's approval.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: skin; targeted-therapy; trialist
- Role: Dermatologist, Mayo Clinic Comprehensive Cancer Center in Arizona
- Specialisms: Basal cell carcinoma; Hedgehog pathway inhibitors; Skin cancer

## Connected records

- cancers: [Locally advanced and metastatic basal cell carcinoma](https://onco.cc/cancers/locally-advanced-bcc/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)
- institutions: [Mayo Clinic Comprehensive Cancer Center in Arizona](https://onco.cc/institutions/mayo-clinic-arizona/)
- key papers: [ERIVANCE BCC: efficacy and safety of vismodegib in advanced basal cell carcinoma](https://onco.cc/key-papers/paper-erivance-vismodegib-sekulic-nejm-2012/)

---
JSON: https://onco.cc/api/v1/entities/aleksandar-sekulic.json